Editas Medicine, Inc. (EDIT) KPIs and segments
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Editas Medicine's business
Coming soon
This tab will track the numbers specific to Editas Medicine's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.
See a number that looks wrong?